NCM Capital Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History

NCM Capital Advisers’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$482K	Sell	1,200 -115	-9%	-$46.1K	1.44%	34
2016 Q2	$459K	Hold	1,315	–	–	1.32%	37
2016 Q1	$474K	Hold	1,315	–	–	1.37%	38
2015 Q4	$714K	Hold	1,315	–	–	2.03%	15
2015 Q3	$612K	Sell	1,315 -1,085	-45%	-$583K	1.81%	18
2015 Q2	$1.22M	Hold	2,400	–	–	1.64%	17
2015 Q1	$1.08M	Hold	2,400	–	–	1.46%	22
2014 Q4	$985K	Hold	2,400	–	–	1.38%	24
2014 Q3	$865K	Sell	2,400 -200	-8%	-$67K	1.3%	32
2014 Q2	$734K	Sell	2,600 -300	-10%	-$88.9K	1.09%	38
2014 Q1	$871K	Sell	2,900 -2,200	-43%	-$678K	1.37%	28
2013 Q4	$1.4M	Sell	5,100 -2,550	-33%	-$733K	1.45%	22
2013 Q3	$2.39M	Sell	7,650 -1,450	-16%	-$381K	2.65%	2
2013 Q2	$2.05M	Buy	+9,100	New	+$2.12M	1.93%	11

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

NCM Capital Advisers's REGN Position: Q3 2016 in Review

NCM Capital Advisers reduced its Regeneron Pharmaceuticals (REGN) stake by 8.7% in Q3 2016, selling an estimated $46.1K and leaving 1,200 shares worth $482K. The position accounts for 1.44% of the portfolio, ranked #34.

NCM Capital Advisers first reported a position in REGN in Q2 2013 and has held it in 14 quarters since. The position peaked at $2.39M in Q3 2013. 554 funds tracked by Wall St. Rank hold REGN as of Q3 2016.

NCM Capital Advisers held 1,200 shares of Regeneron Pharmaceuticals worth $482K as of Q3 2016.
NCM Capital Advisers sold 115 Regeneron Pharmaceuticals shares in Q3 2016, an estimated $46.1K.
Regeneron Pharmaceuticals made up 1.44% of NCM Capital Advisers's portfolio in Q3 2016, its #34 holding.
NCM Capital Advisers first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 14 quarters since.
NCM Capital Advisers's Regeneron Pharmaceuticals position peaked at $2.39M in Q3 2013.
554 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2016.

Based on NCM Capital Advisers's 13F filing for Q3 2016, filed 7 Nov 2016.